MR Imaging Study Using the Northern Alberta Linac-MR (Northern LIGHTs - 1)
ConditionCancer
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorAHS Cancer Control Alberta
About this trial
Cancers are often treated with external beam radiotherapy. Current radiotherapy treatments are performed using computed tomography (also known as CT) scans which may not always clearly identify the cancer. In some instances, magnetic resonance imaging (MRI) may be able to better identify cancers. Therefore, efforts are currently underway to use the MRI scans to improve radiotherapy treatments or eventually even use radiotherapy equipment that only uses MRI scans to guide treatments. This new technology that will only use MRI scans to guide treatments is called the Linac-MR (linear accelerator with an MRI). The purpose of this pilot phase of the study is to test whether the Alberta linac-MR P3 system at the Cross Cancer Institute can acquire high quality MR images safely. It will allow the researchers to develop the best collection of MR images possible with this new machine, in order to allow them to visualize tumors for future patients that are treated on this machine.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Adults ≥ 18 years of age
Patients deemed fit to undergo high dose external beam radiation therapy by their attending radiation oncologist
Disqualifiers
Patients with contraindications for MRI
Patients who are unable to lie flat and still for the duration of the expected scan acquisition
Patients who are unable to provide informed consent
Trial design
Design model
Single group
Treatments tested in this trial
MR scan with the Alberta linac-MR P3 system
DeviceSingle MR imaging session to develop and optimize the necessary MR sequences on the Alberta linac-MR P3 system to allow for MR-guided radiotherapy.
Treatment groups
250 Participants
are divided into 1 treatment groupGroup A: MR Imaging on the Alberta linac-MR P3 systemExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Number of high-quality MR image data sets acquired for each major tumour site (prostate, liver, lung, CNS, breast, gynecological, pancreas, and head and neck)
Clinical radiologists, medical physicists, and radiation oncologists will work together to develop MR sequences that can delineate tumour target volumes on the Alberta linac-MR P3 system. Over the course of the trial, the clinical radiologists will work with medical physicists to optimize these sequences to allow for the development of optimal MR images, with the goal to develop of series of protocols that can be utilized to provide clear MR image guidance for each tumour group.
Time frame
Through study completion, approximately 7 yearsSecondary outcomes
1
Quantify the patient experience on the Linac-MR
Participants will complete a questionnaire at the end of their first scan regarding their experience having imaging done on the Linac-MR. Participants taking part in the optional sub-study will complete the same questionnaire at the end of their last set of imaging.
Time frame
After the first and last scan, up to 5 weeksSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov